Congratulations! You now have unlimited access to all articles from The Cannabis Scientist.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to Application Notes/product profiles
digital magazine subscription
Geoffrey Guy
Chairman and Founder, GW Pharmaceuticals, Cambridge, UK
Research: Creator of approved cannabinoid medicines Sativex and Epidiolex and leader of innovation and new product discovery at GW Pharmaceuticals. Physician in charge of over 300 clinical studies including first-dose-in-man, pharmacokinetics, pharmacodynamics, dose-ranging, controlled clinical trials and large-scale multi-centered studies and clinical surveys.
Unanswered question: We need a better understanding of homeostasis and the role of the cannabinoids in its modulation; specifically in terms of hormesis, cellular bioenergetics, the microbiome, and neural plasticity.
